

Atsushi Oba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5896331/publications.pdf>

Version: 2024-02-01

52
papers

767
citations

567281

15
h-index

552781

26
g-index

54
all docs

54
docs citations

54
times ranked

1044
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Treatment in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 245.	2.8	145
2	Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1373-1383.	1.7	59
3	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020, 272, 731-737.	4.2	49
4	Prognosis Based Definition of Resectability in Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 275, 175-181.	4.2	46
5	Global Survey on Pancreatic Surgery During the COVID-19 Pandemic. <i>Annals of Surgery</i> , 2020, 272, e87-e93.	4.2	42
6	Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography. <i>Hpb</i> , 2018, 20, 708-714.	0.3	31
7	Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 143-155.	2.6	29
8	Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. <i>Scandinavian Journal of Surgery</i> , 2020, 109, 18-28.	2.6	27
9	Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection?. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 35-41.	1.9	24
10	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. <i>Annals of Surgery</i> , 2021, 274, 721-728.	4.2	24
11	New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 725-731.	2.6	24
12	Impact of indocyanine green-fluorescence imaging on distal pancreatectomy with celiac axis resection combined with reconstruction of the left gastric artery. <i>Hpb</i> , 2019, 21, 619-625.	0.3	21
13	Controversial Role of Adjuvant Therapy in Node-Negative Invasive Intraductal Papillary Mucinous Neoplasm. <i>Annals of Surgical Oncology</i> , 2021, 28, 1533-1542.	1.5	20
14	Regional pancreatoduodenectomy <i>versus</i> standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. <i>BJS Open</i> , 2020, 4, 438-448.	1.7	18
15	High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. <i>Pancreatology</i> , 2021, 21, 130-137.	1.1	18
16	Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreatoduodenectomy for Pancreatic Cancer. <i>World Journal of Surgery</i> , 2022, 46, 1172-1182.	1.6	17
17	Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5038-5050.	1.5	16
18	Possible underestimation of blood loss during laparoscopic hepatectomy. <i>BJS Open</i> , 2019, 3, 336-343.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis. <i>British Journal of Surgery</i> , 2022, 109, 450-454.	0.3	13
20	The role of stent placement above the papilla (inside-stent) as a bridging therapy for perihilar biliary malignancy: an initial experience. <i>Surgery Today</i> , 2021, 51, 1795-1804.	1.5	11
21	Sinistral Portal Hypertension after Pancreaticoduodenectomy with Splenic Vein Resection: Pathogenesis and Its Prevention. <i>Cancers</i> , 2021, 13, 5334.	3.7	11
22	Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. <i>British Journal of Surgery</i> , 2021, 108, 115-118.	0.3	11
23	Impact on operative outcomes of laparoscopic simultaneous resection of colorectal cancer and synchronous liver metastases. <i>Asian Journal of Endoscopic Surgery</i> , 2021, 14, 34-43.	0.9	10
24	Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2475-2483.	1.4	10
25	Ductal Dilatation of ≥ 5 mm in Intraductal Papillary Mucinous Neoplasm Should Trigger the Consideration for Pancreatectomy: A Meta-Analysis and Systematic Review of Resected Cases. <i>Cancers</i> , 2021, 13, 2031.	3.7	10
26	Details and Outcomes of Distal Pancreatectomy with Celiac Axis Resection Preserving the Left Gastric Arterial Flow. <i>Annals of Surgical Oncology</i> , 2021, 28, 8283-8294.	1.5	9
27	Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. <i>British Journal of Surgery</i> , 2021, 108, 976-982.	0.3	8
28	Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. <i>Annals of Surgical Oncology</i> , 2022, 29, 378-388.	1.5	8
29	Extent of venous resection during pancreatectomy—finding the balance of technical possibility and feasibility. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2495-2502.	1.4	8
30	Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 4624-4634.	1.5	8
31	Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival. <i>Annals of Surgical Oncology</i> , 2022, 29, 3567-3576.	1.5	5
32	Multifocal/diffuse pancreatic serous cystic neoplasms: Systematic review with a new case. <i>Pancreatology</i> , 2020, 20, 902-909.	1.1	4
33	Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with Videos). <i>Annals of Surgical Oncology</i> , 2022, 29, 3505-3514.	1.5	3
34	ASO Author Reflections: Which Patients with Invasive Intraductal Papillary Mucinous Neoplasm Can Benefit from Adjuvant Therapy?. <i>Annals of Surgical Oncology</i> , 2020, 27, 873-874.	1.5	2
35	The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?. <i>Journal of Clinical Oncology</i> , 2020, 38, 685-685.	1.6	2
36	Hepatic vein resection and reconstruction for liver malignancies: expanding indication and enhancing parenchyma-sparing hepatectomy. <i>BJS Open</i> , 2021, 5, .	1.7	2

#	ARTICLE	IF	CITATIONS
37	Response to the Comment on "Prognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines". <i>Annals of Surgery</i> , 2021, 274, e770-e771.	4.2	2
38	OUP accepted manuscript. <i>British Journal of Surgery</i> , 2022, , .	0.3	2
39	Preoperative Decision to Perform Portal Vein Resection Improves Survival in Patients With Resectable Pancreatic Head Cancer Adjacent to Portal Vein. <i>Annals of Surgery Open</i> , 2021, 2, e064.	1.4	1
40	ASO Author Reflections: The Operative and Perioperative Strategy for Distal Pancreatectomy with Celiac Axis Resection"Can We Improve the Safety for This Morbid Operation?. <i>Annals of Surgical Oncology</i> , 2021, 28, 8295-8296.	1.5	1
41	ASO Visual Abstract: "Details and Outcomes of Distal Pancreatectomy with Celiac Axis Resection Preserving the Left Gastric Arterial Flow. <i>Annals of Surgical Oncology</i> , 2021, 28, 480-480.	1.5	1
42	Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma. <i>Anticancer Research</i> , 2022, 42, 2645-2655.	1.1	1
43	Neoadjuvant therapy using Gemcitabine+nab-paclitaxel for borderline resectable pancreatic head cancers. <i>Suizo</i> , 2021, 36, 73-81.	0.1	0
44	Liposarcoma of gallbladder: a case report and literature review. <i>Journal of Surgical Case Reports</i> , 2021, 2021, rjab273.	0.4	0
45	ASO Visual Abstract: Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. <i>Annals of Surgical Oncology</i> , 2021, 28, 742-743.	1.5	0
46	Conversion surgery for recurrent hepatic angiosarcoma after systemic chemotherapy with paclitaxel. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 427.	0.8	0
47	Trends in long-term survival after liver resection for gastric cancer liver metastasis: Analysis of a single-center experience over 28 years.. <i>Journal of Clinical Oncology</i> , 2022, 40, 290-290.	1.6	0
48	Clinical usefulness of postoperative serum carcinoembryonic antigen in colorectal cancer patients with liver metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, 178-178.	1.6	0
49	ASO Visual Abstract: Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
50	ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
51	ASO Visual Abstract: Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms" A Single-Center, Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
52	ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0